Healthcare Equipment and Supplies
Company Overview of Avinger, Inc.
Avinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells image-guided and catheter-based systems used by physicians to treat patients with peripheral arterial disease (PAD) in the United States and Europe. The company develops lumivascular platform, which integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures. Its lumivascular products include the Lightbox imaging console and Ocelot family of catheters, which are designed to penetrate total arterial blockages, known as chronic total occlusions (CTOs). The company is also developing Pantheris...
400 Chesapeake Drive
Redwood City, CA 94063
Founded in 2007
Key Executives for Avinger, Inc.
Chief Executive Officer, President and Director
Total Annual Compensation: $375.0K
Founder and Executive Chairman
Total Annual Compensation: $335.0K
Chief Financial Officer and Chief Business Officer
Total Annual Compensation: $275.0K
Senior Vice President of Operations and Quality
Total Annual Compensation: $301.3K
Vice President of Business Development
Total Annual Compensation: $362.9K
Compensation as of Fiscal Year 2015.
Avinger, Inc. Key Developments
Avinger Announces Expanded FDA Indications for Pantheris™ as Diagnostic Imaging Device
Oct 19 16
Avinger, Inc. announced that the company has received expanded indications from the U.S. Food and Drug Administration (FDA) recognizing the Pantheris™ Lumivascular atherectomy system as a technology that can be used for both therapeutic and diagnostic purposes. Pantheris is the first and only image-guided atherectomy device to receive clearance for diagnostic imaging as well as for the simultaneous treatment of PAD. This expanded indication clarifies that, in addition to treatment of PAD, Pantheris may be used by physicians to identify the vessel lumen and wall structures such as intima, internal elastic lamina (IEL), media, external elastic lamina (EEL) and stent struts, as well as vessel morphologies such as calcium, thrombus, fibroatheromas, and necrotic cores. Atherectomy is a minimally invasive treatment for PAD in which a catheter-based device is used to remove plaque from a blood vessel. Lumivascular technology in the Pantheris catheter allows physicians, for the first time ever, to see from inside the artery during a directional atherectomy procedure by using an imaging modality called optical coherence tomography, or OCT. With the Lumivascular approach, physicians can more accurately navigate their devices to treat PAD lesions using the guidance of OCT images generated from inside the artery. By relying upon OCT images as an adjunct to fluoroscopy, exposure to ionizing radiation may be reduced for healthcare workers and patients.
Avinger, Inc Signs Agreement with Healthtrust for Lumivascular Technology
Sep 7 16
Avinger, Inc. announced it has signed an agreement with HealthTrust. The agreement establishes terms under which members of the HealthTrust group purchasing organization may acquire Avinger's portfolio of technologies designed to treat PAD, including Avinger's Pantheris™ Optical Coherence Tomography (OCT) image-guided atherectomy system, which recently received 510(k) clearance from the United States Food & Drug Administration (FDA). The agreement becomes effective September 15, 2016. Pantheris is a minimally invasive treatment for peripheral artery disease in which a catheter-based device is used to remove plaque from a blood vessel. Lumivascular technology utilized in the Pantheris system allows physicians to see from within the artery, enabling them to precisely remove plaque, leaving the healthy arterial structures intact. In addition, Pantheris visualizes the artery without requiring ionizing radiation, or toxic contrast medium (dye) injections, offering the potential to reduce physician, staff and patient X-ray exposure, as well as minimize patient complications related to contrast exposure.
Avinger Seeks Acquisitions
Aug 11 16
Avinger, Inc. (NasdaqGM : AVGR) plans to raise gross proceeds of approximately $30 million and use it for general corporate purposes, including working
capital, capital expenditures, other corporate expenses and acquisitions of complementary products, technologies or businesses.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|